ArticleHereditas2026
Curcumin inhibits chondrocyte apoptosis and inflammation in osteoarthritis via the miR-338-3p/EIF4A1 signaling axis.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOsteoarthritis (OA) is a degenerative joint disorder mainly characterized by articular cartilage degradation. Curcumin, the primary bioactive compound derived from turmeric, exhibits anti-inflammatory, antioxidant, and anti-catabolic activities. This study aimed to explore the therapeutic potential of curcumin in OA and its underlying mechanism involving the microRNA-338-3p (miR-338-3p)/Eukaryotic Translation Initiation Factor 4A1 (EIF4A1) signaling pathway.
methodsMouse models of OA were established, including groups treated with curcumin or intra-articular injection of miR-338-3p agomir, along with an in vitro chondrocyte model. Modulation of miR-338-3p and EIF4A1 expression was achieved through siRNA interference. Gene expression was quantified via quantitative real-time polymerase chain reaction and Western blot; the targeting interaction between miR-338-3p and EIF4A1 was confirmed using a luciferase reporter assay; and cellular viability and inflammatory mediator levels were evaluated with Cell Counting Kit-8, flow cytometry, and enzyme-linked immunosorbent assay. Cartilage tissue pathology was also examined.
resultsEIF4A1 was markedly upregulated in OA cartilage, whereas miR-338-3p targeted and suppressed EIF4A1 expression. Curcumin administration elevated miR-338-3p levels and reduced EIF4A1 expression. Moreover, curcumin, miR-338-3p overexpression, and EIF4A1 knockdown attenuated chondrocyte apoptosis, enhanced proliferation, and modulated apoptosis-related protein expression (decreasing cleaved caspase-3 and Bax, increasing Bcl-2). Curcumin also suppressed the secretion of inflammatory cytokines (IL-6, TNF-α, IL-1β, etc.), decreased synthesis of matrix-degrading enzymes (Matrix Metalloproteinase-13 (MMP13), A Disintegrin and Metalloproteinase with Thrombospondin Motifs (ADAMTS)), and reduced OARSI scores, ultimately ameliorating OA progression.
conclusionThese results demonstrate that curcumin mitigates chondrocyte apoptosis, attenuates cartilage inflammation, and downregulates joint matrix-degrading enzyme expression in OA through the miR-338-3p/EIF4A1 axis, suggesting this pathway as a promising target for gene therapy in OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.